GlobeNewswire: Zosano Pharma Corporation Contains the last 10 of 175 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T08:50:26ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/06/02/2455162/0/en/Zosano-Pharma-Files-Voluntary-Petition-for-Relief-Under-Chapter-11.html?f=22&fvtc=4&fvtv=24275Zosano Pharma Files Voluntary Petition for Relief Under Chapter 112022-06-02T12:00:00Z<![CDATA[FREMONT, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 (“Chapter 11”) of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the company.]]>https://www.globenewswire.com/news-release/2022/05/13/2443252/0/en/Zosano-Pharma-Reports-First-Quarter-2022-Financial-Results.html?f=22&fvtc=4&fvtv=24275Zosano Pharma Reports First Quarter 2022 Financial Results2022-05-13T20:00:00Z<![CDATA[FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results and statements has been retroactively adjusted to give effect to our April 11, 2022 1-for-35 reverse stock split.]]>https://www.globenewswire.com/news-release/2022/04/29/2432920/0/en/Zosano-Pharma-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=24275Zosano Pharma Provides Corporate Update2022-04-29T20:00:00Z<![CDATA[FREMONT, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update.]]>https://www.globenewswire.com/news-release/2022/04/11/2420006/0/en/Zosano-Pharma-Announces-Reverse-Stock-Split-Effective-Today.html?f=22&fvtc=4&fvtv=24275Zosano Pharma Announces Reverse Stock Split Effective Today2022-04-11T12:00:00Z<![CDATA[ZSAN common stock expected to begin trading on a split-adjusted basis on April 12, 2022 ZSAN common stock expected to begin trading on a split-adjusted basis on April 12, 2022]]>https://www.globenewswire.com/news-release/2022/03/17/2405636/0/en/Zosano-Pharma-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results.html?f=22&fvtc=4&fvtv=24275Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results2022-03-17T20:05:00Z<![CDATA[FREMONT, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2021, as well as business updates.]]>https://www.globenewswire.com/news-release/2022/02/09/2381467/0/en/Zosano-Pharma-Announces-Pricing-of-15-4-Million-Public-Offering-of-Common-Stock-and-Warrants.html?f=22&fvtc=4&fvtv=24275Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants2022-02-09T02:55:26Z<![CDATA[FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $0.30 per unit. The warrants have an exercise price of $0.30 per share, are immediately exercisable and will expire five years from the date of issuance. Zosano has granted the underwriter a 30-day option to purchase up to an additional 7,687,500 shares of common stock and/or additional warrants to purchase up to 7,687,500 shares of common stock.]]>https://www.globenewswire.com/news-release/2022/02/08/2381351/0/en/Zosano-Pharma-Announces-Proposed-Public-Offering-of-Common-Stock-and-Warrants.html?f=22&fvtc=4&fvtv=24275Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants2022-02-08T21:10:00Z<![CDATA[FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock. All of the units in the offering are to be sold by Zosano. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.]]>https://www.globenewswire.com/news-release/2022/01/05/2361916/0/en/CORRECTION-Zosano-Pharma-Announces-Publication-of-Clinical-Data-Demonstrating-Comparable-Immunogenicity-of-a-Trivalent-Influenza-Vaccine-Formulated-on-its-Transdermal-Microneedle-S.html?f=22&fvtc=4&fvtv=24275CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose2022-01-05T17:01:21Z<![CDATA[—Data published in the Journal of Vaccines and Immunology— —Data published in the Journal of Vaccines and Immunology—]]>https://www.globenewswire.com/news-release/2022/01/05/2361788/0/en/Zosano-Pharma-Announces-Publication-of-Clinical-Data-Demonstrating-Comparable-Immunogenicity-of-a-Trivalent-Influenza-Vaccine-Formulated-on-its-Transdermal-Microneedle-System-Versu.html?f=22&fvtc=4&fvtv=24275Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose2022-01-05T14:20:00Z<![CDATA[—Data published in the Journal of Vaccines and Immunology— —Data published in the Journal of Vaccines and Immunology—]]>https://www.globenewswire.com/news-release/2021/12/13/2351191/0/en/Zosano-Pharma-Announces-Changes-to-Board-of-Directors-Appoints-Cross-Functional-Business-Executive-Elaine-M-Yang.html?f=22&fvtc=4&fvtv=24275Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang2021-12-13T21:30:00Z<![CDATA[FREMONT, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang.]]>